Skip Nav Destination
Issues
1 June 2006
-
Cover Image
Cover Image
Subcellular colocalization of an anti-p97 antibody-drug conjugate with a lysosomal marker in melanoma cells. SK-MEL-5 cells were treated with the anti-p97 antibody-auristatin conjugate, L49-vcMMAF, directly labeled with Alexa Fluor 594 for 48 hours. L49-vcMMAF (red) and the lysosomal marker CD107a (green) colocalize (yellow) in melanoma cells that are effectively killed by L49-vcMMAF. Chromosomal DNA is stained with DAPI (blue). For antibody-drug conjugates targeting p97, both antigen level and trafficking to the lysosomes are important factors for achieving robust in vitro cytotoxicity against cancer cells. For details, see Smith et al. in this issue. - PDF Icon PDF LinkTable of Contents
ISSN 1535-7163
EISSN 1538-8514
Editorial
Reviews
Research Articles: Targets
Research Articles: Therapeutics
Nitric oxide–releasing aspirin and indomethacin are potent inhibitors against colon cancer in azoxymethane-treated rats: effects on molecular targets
Chinthalapally V. Rao; Bandaru S. Reddy; Vernon E. Steele; C-X Wang; Xiaoping Liu; Nengtai Ouyang; Jagan M.R. Patlolla; Barbara Simi; Levy Kopelovich; Basil Rigas
Constitutively active receptor tyrosine kinases as oncogenes in preclinical models for cancer therapeutics
Kristen A. Kellar; Matthew V. Lorenzi; Ching Ping Ho; Dan You; Mei-Li Wen; Rolf P. Ryseck; Simone Oppenheimer; Brian E. Fink; Gregory D. Vite; Bruce R. Rowley; Chiang Yu; David K. Bol; Francis Y. Lee; Tai W. Wong
Research Articles: Development
Advertisement
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.